Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Executive Summary
Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.
You may also be interested in...
Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects
If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.